Expression of DLL3 in small cell lung cancer and its application in targeted therapy

VernacularTitle:DLL3在小细胞肺癌中的表达及其在靶向治疗中的应用
Author: Hao ZUO ¹ ; Na LI ; Luojun CHEN ; Huali LIU ; Qibin SONG
Author Information

1. 武汉大学人民医院肿瘤中心 430060
Keywords: Small cell lung carcinoma; Receptors,Notch; Delta-like protein 3
From: Journal of International Oncology 2019;46(6):366-369
CountryChina
Language:Chinese
Abstract: Small cell lung cancer (SCLC) has a poor biological behavior,high probability of recurrence and metastasis,and limited treatment.The Notch signaling pathway is an evolutionarily conserved pathway that regulates the growth of many cell types through local cell-cell interactions.It controls the differentiation,proliferation and survival of cells.As a ligand for the Notch pathway,delta-like protein 3 (DLL3) is highly expressed on the membrane of SCLC cells.DLL3 plays an important role in cancer initiation and epithelial mesenchymal transition,invasion and metastasis of SCLC.Rovalpituzumab tesirine is a conjugate of directed against DLL3,which shows great potential for SCLC therapy.